Rare diseases affect close to 30 million people in the EU-27 and despite the high quality of public research and the existence of 'centres of excellence', there is a lack of innovative approaches for the development of new therapies. The definition of optimised methods and resources use requires coordination in both investments and infrastructures that only a Public Private Partnership approach can supply. The conference will explore how to leverage existing models to promote best practises in the field.
Speakers include researchers from rare disease centres in France, Italy, U.K. and Germany.
